Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | BMEA |
---|---|---|
09:32 ET | 14034 | 5.582 |
09:34 ET | 13684 | 5.7932 |
09:36 ET | 2833 | 5.78 |
09:38 ET | 2402 | 5.7001 |
09:39 ET | 3146 | 5.76 |
09:41 ET | 8852 | 5.6047 |
09:43 ET | 4872 | 5.68 |
09:45 ET | 11502 | 5.76 |
09:48 ET | 4002 | 5.765 |
09:50 ET | 7133 | 5.7458 |
09:52 ET | 5634 | 5.62 |
09:54 ET | 7039 | 5.63 |
09:56 ET | 10714 | 5.65 |
09:57 ET | 2074 | 5.72 |
09:59 ET | 4877 | 5.69 |
10:01 ET | 10871 | 5.68 |
10:03 ET | 14075 | 5.72 |
10:06 ET | 6550 | 5.72 |
10:08 ET | 19876 | 5.765 |
10:10 ET | 9821 | 5.675 |
10:12 ET | 5679 | 5.72 |
10:14 ET | 3415 | 5.72 |
10:15 ET | 14405 | 5.77 |
10:17 ET | 5365 | 5.745 |
10:19 ET | 1600 | 5.759 |
10:21 ET | 6273 | 5.78 |
10:24 ET | 8795 | 5.83 |
10:26 ET | 19546 | 5.85 |
10:28 ET | 10365 | 5.9094 |
10:30 ET | 3110 | 5.86 |
10:32 ET | 9155 | 5.918 |
10:33 ET | 21123 | 5.9 |
10:35 ET | 28354 | 5.93 |
10:37 ET | 22278 | 5.9911 |
10:39 ET | 36554 | 6 |
10:42 ET | 20362 | 5.995 |
10:44 ET | 9826 | 6.03 |
10:46 ET | 16355 | 6.03 |
10:48 ET | 21467 | 6.085 |
10:50 ET | 30638 | 6.05 |
10:51 ET | 5525 | 6.0222 |
10:53 ET | 15524 | 5.995 |
10:55 ET | 13371 | 6 |
10:57 ET | 26176 | 6 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Biomea Fusion Inc | 166.4M | -1.7x | --- |
Compass Therapeutics Inc. | 165.1M | -3.4x | --- |
Galectin Therapeutics Inc | 169.7M | -3.7x | --- |
Acumen Pharmaceuticals Inc | 162.2M | -2.5x | --- |
Boundless Bio Inc | 171.8M | 0.0x | --- |
Atossa Therapeutics Inc | 161.0M | -5.1x | --- |
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $166.4M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 35.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.57 |
Book Value | $4.72 |
P/E Ratio | -1.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.